Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Nab-paclitaxel

Nab-paclitaxel

15 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Nab-paclitaxel

129 trials tracked of Nab-paclitaxel: 26 in phase 3 or 4 and 18 with published results. The most-cited published study has 4493 citations.

129Trials tracked
26Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 1 Phase 3 25 Phase 2 93 Phase 1 10
  1. Phase 3 A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130) Completed · 4,493 cited
  2. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Completed · 1,862 cited
  3. Phase 3 A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Completed · 1,659 cited
  4. Phase 3 A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer Completed · 1,104 cited
  5. Phase 3 A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Completed · 555 cited
  6. Phase 3 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment Completed · 515 cited
Show 44 more trials
  1. Phase 3 A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer Completed · 393 cited
  2. Phase 3 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Completed · 143 cited
  3. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer Completed · 114 cited
  4. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Completed · 56 cited
  5. Phase 3 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) Completed · 48 cited
  6. Phase 3 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed · 36 cited
  7. Phase 3 A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131] Completed · 25 cited
  8. Phase 3 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine Completed · 24 cited
  9. Phase 3 A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Completed · 20 cited
  10. Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Completed · 16 cited
  11. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) Completed · 6 cited
  12. Phase 3 Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer Completed · 5 cited
  13. Phase 4 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed
  14. Phase 3 Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Completed
  15. Phase 3 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Completed
  16. Phase 3 A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer Completed
  17. Phase 3 Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Completed
  18. Phase 3 Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Completed
  19. Phase 3 Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer Completed
  20. Phase 3 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed
  21. Phase 2 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Completed
  22. Phase 2 Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer Completed
  23. Phase 2 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Completed
  24. Phase 2 A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Completed
  25. Phase 2 A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Completed
  26. Phase 2 A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC Completed
  27. Phase 2 Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers Completed
  28. Phase 2 A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer Completed
  29. Phase 2 BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Completed
  30. Phase 2 Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer Completed
  31. Phase 2 Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel Completed
  32. Phase 2 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed
  33. Phase 2 Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer Completed
  34. Phase 2 Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers Completed
  35. Phase 2 Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer Completed
  36. Phase 2 A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer Completed
  37. Phase 2 Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Completed
  38. Phase 2 Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC Completed
  39. Phase 2 Intravesicular Abraxane for Treatment-Refractory Bladder Cancer Completed
  40. Phase 2 Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer Completed
  41. Phase 2 Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer Completed
  42. Phase 2 Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer Completed
  43. Phase 2 Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy Completed
  44. Phase 2 Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma Completed

Showing the 50 most-cited and recently-updated of 129 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
ICI-based therapy may improve overall survival in patients with primary pulmonary choriocarcinoma
Oncology Sys. Review
ICI-based therapy may improve overall survival in patients with primary pulmonary choriocarcinoma Immunotherapy may extend life for men with rare lung cancer
This case report and literature review examines the management of primary pulmonary choriocarcinoma in a male patient. The authors suggest t…
A rare and aggressive lung cancer in men is showing signs of better survival when treated with immunotherapy drugs.
Frontiers Oct 21, 2026
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse
Rheumatology Sys. Review
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse Long Survival in Pancreatic Cancer Can Bring Brain Spread
This case report describes a 51-year-old man with metastatic pancreatic ductal adenocarcinoma who survived 30 months from diagnosis and 3.5 …
A single case shows pancreatic cancer that responds to treatment may later reach the brain, even after 30 months.
Frontiers Oct 12, 2026
Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancer
Oncology Meta-analysis
Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancer Transcriptomic Signatures May Help Predict Pancreatic Cancer Outcomes
This retrospective pooled analysis of phase 2 trials evaluates transcriptomic signatures and GemPred status in patients with metastatic panc…
New research suggests that specific genetic markers in pancreatic cancer may help predict how well different chemotherapy treatments will wo…
Oct 10, 2026
Comparative Efficacy of Modified FOLFIRINOX and Gemcitabine plus Nab-paclitaxel in Pancreatic Cancer
Oncology Meta-analysis
Comparative Efficacy of Modified FOLFIRINOX and Gemcitabine plus Nab-paclitaxel in Pancreatic Cancer Comparing Two Main Chemotherapy Options for Patients with Pancreatic Cancer
A meta-analysis of 1,204 patients reveals that gemcitabine plus nab-paclitaxel provides superior survival outcomes compared to modified FOLF…
A large review of over 1,200 patients shows that one common drug combination may offer better survival rates than another.
Frontiers Sep 28, 2026
Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer
Oncology Sys. Review
Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer New Treatment Approach Shows Success for a Rare Type of Lung Cancer
This case report describes a 61-year-old man with high-grade thoracic malignancy who achieved a pathologic complete response and undetectabl…
A 61-year-old man with a rare lung cancer showed a complete response after receiving a specific mix of drugs and surgery.
Frontiers Sep 8, 2026
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel
Oncology RCT
MULTIPL biomarker identifies patients with significantly longer overall survival on gemcitabine plus nab-paclitaxel Trial Shows Biomarker Helps Identify Best Treatment for Pancreatic Cancer
This randomized Phase II trial and training cohort evaluated the MULTIPL biomarker in 160 and 268 patients with metastatic pancreatic ductal…
A new biomarker tool may help doctors choose the most effective chemotherapy for patients with metastatic pancreatic cancer.
medRxiv Aug 28, 2026
Ivonescimab-containing chemoimmunotherapy can trigger rare ADAMTS13 inhibitor-positive immune thrombotic thrombocytopenic purpura
Allergy & Immunology Sys. Review
Ivonescimab-containing chemoimmunotherapy can trigger rare ADAMTS13 inhibitor-positive immune thrombotic thrombocytopenic purpura New Case Highlights Rare Kidney Risk in Lung Cancer Treatment
This case report and literature review describes a patient with stage IVB lung adenocarcinoma who developed iTTP after receiving an ivonesci…
A single case report identifies a rare blood and kidney condition that can occur during specific lung cancer treatments involving ivonescima…
Frontiers Aug 4, 2026
Pyrotinib-based regimen achieves pathological complete response after non-response to standard neoadjuvant therapy in HER2+ breast cancer
Rheumatology Sys. Review
Pyrotinib-based regimen achieves pathological complete response after non-response to standard neoadjuvant therapy in HER2+ breast cancer Case shows new drug combo may help breast cancer patient
This case report and literature review describes a patient with HER2+/HR+ breast cancer who achieved total pathological complete response af…
A woman with HER2-positive breast cancer achieved complete response after switching to a pyrotinib-based regimen when standard therapy faile…
Frontiers Jul 25, 2026
Neoadjuvant gemcitabine plus nab-paclitaxel vs gemcitabine plus S-1 for geriatric pancreatic cancer
Oncology RCT
Neoadjuvant gemcitabine plus nab-paclitaxel vs gemcitabine plus S-1 for geriatric pancreatic cancer Trial tests two chemo combos for older pancreatic cancer patients
This Phase III randomized controlled trial is evaluating neoadjuvant gemcitabine plus nab-paclitaxel compared to gemcitabine plus S-1 in 400…
A new trial compares two chemotherapy combinations for older adults with resectable pancreatic cancer.
Jul 12, 2026
Paclitaxel monotherapy shows modest activity in relapsed small cell lung cancer
Oncology Meta-analysis
Paclitaxel monotherapy shows modest activity in relapsed small cell lung cancer Nab-paclitaxel shows similar results to paclitaxel for lung cancer
This meta-analysis examined paclitaxel monotherapy in relapsed small cell lung cancer. The 3-month progression-free survival rate was modest…
New data compares two types of paclitaxel treatments for relapsed small cell lung cancer, showing similar safety and effectiveness.
Jul 3, 2026
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer
Drug Pipeline Meta-analysis
Nab-paclitaxel provides moderate efficacy and manageable safety for advanced or recurrent small cell lung cancer Nab-paclitaxel shows moderate results for advanced small cell lung cancer
This meta-analysis of 334 patients with advanced or recurrent small cell lung cancer found nab-paclitaxel achieved an overall response rate …
A new analysis shows nab-paclitaxel offers manageable safety and steady results for patients with advanced small cell lung cancer.
Frontiers Jun 13, 2026
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer
Oncology RCT
THP shows noninferior pCR rates compared to TCbHP in HER2-positive invasive breast cancer Trial shows omitting carboplatin maintains success in breast cancer
This Phase III randomized controlled trial of 766 women with untreated, stage II and III, HER2-positive invasive breast cancer found that th…
A new clinical trial shows that removing one specific drug can lower severe side effects while maintaining high success rates for certain br…
Jun 12, 2026

All Nab-paclitaxel Articles